Efgartigimod PH20 SC
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
New Onset Generalized Myasthenia Gravis (gMG)
Conditions
New Onset Generalized Myasthenia Gravis (gMG)
Trial Timeline
Apr 17, 2025 → May 1, 2027
NCT ID
NCT06909214About Efgartigimod PH20 SC
Efgartigimod PH20 SC is a approved stage product being developed by Argenx for New Onset Generalized Myasthenia Gravis (gMG). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06909214. Target conditions include New Onset Generalized Myasthenia Gravis (gMG).
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07264426 | Pre-clinical | Recruiting |
| NCT06909214 | Approved | Recruiting |
| NCT06684847 | Phase 3 | Recruiting |
| NCT06637072 | Approved | Active |
| NCT06392386 | Phase 2/3 | Recruiting |
| NCT05979441 | Phase 3 | Recruiting |
| NCT04812925 | Phase 3 | Active |
| NCT04818671 | Phase 3 | Completed |
| NCT04687072 | Phase 3 | Completed |
| NCT04280718 | Phase 2 | Active |
Competing Products
20 competing products in New Onset Generalized Myasthenia Gravis (gMG)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| 50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125 | Cassava Sciences | Phase 1 | 25 |
| E2007 | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Pre-clinical | 23 |
| perampanel + perampanel | Eisai | Phase 1 | 33 |
| Perampanel and Microgynon-30 + Perampanel and Microgynon-30 | Eisai | Phase 1 | 33 |
| Perampanel | Eisai | Pre-clinical | 23 |
| Zonisamide + Placebo | Eisai | Phase 3 | 77 |
| Perampanel + Placebo | Eisai | Phase 3 | 77 |
| Rufinamide | Eisai | Phase 3 | 77 |
| Eslicarbazepine Acetate tablets | Eisai | Pre-clinical | 23 |
| Perampanel | Eisai | Pre-clinical | 23 |
| Perampanel | Eisai | Approved | 85 |
| Zonisamide tablets | Eisai | Pre-clinical | 23 |
| Perampanel | Eisai | Phase 3 | 77 |
| Eslicarbazepine acetate + Eslicarbazepine acetate | Sumitomo Pharma | Phase 3 | 77 |
| BGG492 | Novartis | Phase 2 | 52 |
| Cyclosporine - cyclosporine microemulsion | Novartis | Approved | 85 |
| Investigational new drug, company code: BGG492 + Placebo + Investigational new drug, company code: BGG492 | Novartis | Phase 2 | 52 |
| Canakinumab | Novartis | Phase 3 | 77 |
| Everolimus + Ranibizumab | Novartis | Phase 2 | 52 |